Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Induced proximity-based drug discovery at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

18 organizations at Discovery on Target 2026 present work in induced proximity: 8 academic, government and non-profit bodies, 5 drug developers and 5 technology and service providers. Between them they bring 45 presentations to the program. Most represented: AstraZeneca (7 on the program), Novartis (5 on the program), Foghorn Therapeutics (3 on the program). As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–10 of 18 organizations

Organization	Discovery on Target 2026 Attendance
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global biopharmaceutical company with medicines in oncology, cardiovascular, respiratory, immunology and rare diseases.	Chair Mon Sep 28 1:30pm–1:35pm Chairperson's Remarks Symposium: Induced Proximity-Based Drug Discovery Panel Tue Sep 29 11:05am–12:05pm Defining Next-Generation Radioligand Therapies: From Molecular Design to Clinical and Commercial Success Radioligand Therapies · with Normunity, Lumina Pharmaceuticals, Ratio Therapeutics +2 more Talk Tue Sep 29 1:50pm–2:20pm From Imaging to Impact: Practical Frameworks for Personalized Dosimetry in Radioligand Therapy Radioligand Therapies Talk Tue Sep 29 2:50pm–3:20pm DegDig: Digging the Fate of Proteins under Degrader Control by Multiplexed Target‑Guided Proteomics in a 384 Well Format Innovative Discovery Technologies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 9:05am–9:35am Advancements in ADCs: Current Trends in Bioconjugation and Site-Specific Conjugation Strategies Next-Generation Conjugates Talk Wed Sep 30 2:05pm–2:35pm Reduced Time-Point Dosimetry in Radioconjugate Therapy: From Preclinical Models to Clinical Translation Radioligand Therapies Panel Wed Sep 30 3:05pm–4:05pm From Target to Therapy: Science, Strategy, and Scalability Radioligand Therapies · with Perceptive, Curium, Mariana Oncology +1 more Panel Thu Oct 1 7:30am–8:15am Connect the DOTs: Career Growth Opportunities Plenary · with Avacta Therapeutics
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company; Novartis Biomedical Research is its drug discovery arm.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with Barcelona Supercomputing Center, InduPro, Foghorn Therapeutics Talk Tue Sep 29 2:20pm–2:50pm From PSMA to What’s Next: Evolving the Radioligand Target Landscape Radioligand Therapies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 2:05pm–2:35pm Exploring the Impact of Ligand and Payload Design on ADC Therapeutic Index Using Quantitative Systems Pharmacology and Physiologically Based Pharmacokinetic Modeling Next-Generation Conjugates Panel Thu Oct 1 7:30am–8:15am Direct-to-Biology (D2B) Lead Generation Strategies
Foghorn Therapeutics Cambridge, MA
foghorntx.com Biotech Clinical-stage biotech targeting the chromatin regulatory system with small molecules and protein degraders for cancer.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with Barcelona Supercomputing Center, InduPro, Novartis Talk Mon Sep 28 3:05pm–3:35pm Rewiring Transcription via Induced Proximity Symposium: Induced Proximity-Based Drug Discovery Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Novel Drug Modalities Talk Thu Oct 1 9:05am–9:25am First-in-Class ARID1B Degraders Enable Targeting of ARID1A-Mutant Cancers Novel Drug Modalities
Dana-Farber Cancer Institute Boston, MA
dana-farber.org Academic & healthcare Harvard-affiliated cancer treatment and research center in Boston.	Talk Mon Sep 28 1:35pm–2:05pm Targeting p53 Protein Abundance across TP53 Mutant Cancers with Proximity-Inducing Small Molecules Symposium: Induced Proximity-Based Drug Discovery Talk Mon Sep 28 4:00pm–4:30pm Selectively Targeting Cancer Dependency for Novel Therapy Development Symposium: Induced Proximity-Based Drug Discovery Talk Thu Oct 1 4:35pm–5:05pm Proteolysis Activity Mapping and Substrate Discovery Platform for Identifying Tumor-Activated Biosensors Innovative Discovery Technologies
Yale University New Haven, CT
	Talk Mon Sep 28 9:15am–9:45am Enhancing Inhibition via Chemically Induced Proximity: A RIPTAC Targeting BCL6 and BET Proteins Symposium: Induced Proximity-Based Drug Discovery Talk Tue Sep 29 1:50pm–2:20pm Using DNA-Encoded Libraries to Discover Molecular Glues that bind FKBP12 and Structurally Distinct Targets Lead Generation Strategies Talk Wed Sep 30 3:35pm–4:05pm POSTER SPOTLIGHT: Development of CORTACs as a Small Molecule Strategy to Enhance Degrader Specificity Emerging Drug Targets
Frontier Medicines
frontiermeds.com Biotech Biotech combining chemoproteomics, covalent chemistry and machine learning to drug hard-to-target proteins in cancer and immunology.	Chair Mon Sep 28 9:10am–9:15am Chairperson's Remarks Symposium: Induced Proximity-Based Drug Discovery Chair Tue Sep 29 8:30am–8:35am Chairperson's Remarks Lead Generation Strategies Talk Tue Sep 29 11:35am–12:05pm Breaking In: How Covalent AI Is Picking the Lock on Undruggable Proteins Innovative Discovery Technologies Panel Wed Sep 30 4:50pm–5:50pm Venture-Capitalist Insights on Trends in Drug Discovery Plenary · with Curie.Bio, General Inception, Lilly Asia Ventures +3 more
WuXi AppTec Shanghai, China	◆Premier Sponsor
wuxiapptec.com CROs & CDMOsPremier Sponsor Chinese contract research, development and manufacturing group covering chemistry, biology, DNA-encoded library screening, testing and production for drug developers.	Booth Exhibiting at Booth 403 Tue, Sep 293:50pm–7:00pmWed, Sep 3011:05am–4:50pmThu, Oct 111:05am–2:15pm Talk Tue Sep 29 3:20pm–3:50pm Exploration of Novel E3 Ligase to Support Targeted Protein Degradation Drug Discovery Novel Drug Modalities Talk Thu Oct 1 1:00pm–1:30pm Accelerating the Discovery of Next-Gen Oligonucleotide Conjugates: From Hit Identification to CMC Readiness Next-Generation Conjugates
Stanford University Stanford, CA
stanford.edu Academic & healthcare Private research university in California's Bay Area with a large school of medicine.	Talk Mon Sep 28 10:15am–10:45am A Bivalent Molecular Glue Linking Acetyltransferases to Oncogene-Induced Cell Death Symposium: Induced Proximity-Based Drug Discovery Talk Mon Sep 28 2:35pm–3:05pm Discovery and Optimization of TRIM21 Molecular Glues That Induce Potent Nuclear Pore Complex Degradation Symposium: Induced Proximity-Based Drug Discovery
University of Minnesota Minneapolis, MN
	Talk Mon Sep 28 2:05pm–2:35pm Not Your Average BRD4 Inhibitor- Selective Inhibitor and Degrader Approaches for Anti-Cancer and Anti-Inflammatory Epigenetic Therapy Symposium: Induced Proximity-Based Drug Discovery Talk Wed Sep 30 10:35am–10:50am POSTER SPOTLIGHT: Single Domain Antibodies Targeting the Third Intracellular Loop Are Receptor Subtype-Selective Allosteric Modulators Lead Generation Strategies
Barcelona Supercomputing Center Barcelona, Spain
bsc.es Academic & healthcare Spain's national supercomputing center, with research groups in computational life sciences.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with InduPro, Foghorn Therapeutics, Novartis Talk Wed Sep 30 10:35am–11:05am Rational Ligase and Molecular Glues Screening Made Easy with Smart Modeling Novel Drug Modalities